KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$27.1 million.

  • Neogenomics' Income from Continuing Operations fell 53.28% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 45.98%. This contributed to the annual value of -$78.7 million for FY2024, which is 10.51% up from last year.
  • Latest data reveals that Neogenomics reported Income from Continuing Operations of -$27.1 million as of Q3 2025, which was up 39.84% from -$45.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Income from Continuing Operations ranged from a high of $75.9 million in Q2 2021 and a low of -$49.4 million during Q1 2022.
  • Over the past 3 years, Neogenomics' median Income from Continuing Operations value was -$24.3 million (recorded in 2023), while the average stood at -$24.1 million.
  • The largest annual percentage gain for Neogenomics' Income from Continuing Operations in the last 5 years was 1,211.86% (2021), contrasted with its biggest fall of 895.78% (2021).
  • Quarterly analysis of 5 years shows Neogenomics' Income from Continuing Operations stood at -$41.8 million in 2021, then soared by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then declined by 6.97% to -$15.3 million in 2024, then tumbled by 53.28% to -$27.1 million in 2025.
  • Its Income from Continuing Operations was -$27.1 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$25.9 million in Q1 2025.